Equities

ProKidney Corp

PROK:NAQ

ProKidney Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.83
  • Today's Change0.14 / 8.28%
  • Shares traded380.45k
  • 1 Year change+6.40%
  • Beta1.3498
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

  • Revenue in USD (TTM)0.00
  • Net income in USD-45.61m
  • Incorporated2021
  • Employees163.00
  • Location
    ProKidney Corp2000 Frontis Plaza Blvd., Suite 250WINSTON-SALEM 27103United StatesUSA
  • Phone+1 (336) 999-7028
  • Websitehttps://prokidney.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
OmniAB Inc20.41m-63.02m471.27m106.00--1.71--23.09-0.6227-0.62270.20172.430.0564--4.24192,537.70-17.43---18.43-------308.78------0.00---42.17---126.65------
Regenxbio Inc84.33m-238.81m475.14m344.00--1.57--5.63-5.03-5.031.766.090.1463--3.27245,136.60-41.43-16.75-51.75-19.0854.3678.27-283.19-72.06----0.00---19.94-16.216.00---5.59--
Cartesian Therapeutics Inc47.94m-244.83m479.58m38.00--569.13--10.00-37.79-37.793.250.03150.1708--9.861,261,526.00-87.23-43.66-94.16-66.84-----510.72-136.35---0.35050.00---76.5395.83-721.02---25.27--
GH Research PLC-100.00bn-100.00bn482.30m49.00--2.50----------3.64----------------------------0.0039-------58.47------
Celcuity Inc0.00-93.97m489.74m55.00--3.45-----2.61-2.610.004.030.00----0.00-45.24-37.32-49.93-39.16------------0.393-------57.99---31.12--
Korro Bio Inc0.00-101.60m490.05m95.00--2.70-----17.04-17.040.0019.280.00----0.00-70.10-31.55-76.20-36.48-------365.87---104.930.00------0.5001--78.21--
Terns Pharmaceuticals Inc0.00-88.07m491.80m66.00--1.35-----1.18-1.180.004.290.00----0.00-27.10-41.34-28.12-45.70-------31,010.30----0.00-------49.49---26.60--
ProKidney Corp0.00-45.61m492.91m163.00---------0.5541-0.55410.00-3.360.00----0.00-29.48------------------0.0003------67.17------
Kalvista Pharmaceuticals Inc0.00-141.77m498.18m150.00--2.51-----3.54-3.540.004.010.00----0.00-78.65-40.63-87.52-43.67-------2,972.81----0.00-------36.31---16.34--
Zenas Biopharma Inc0.00-128.97m501.49m115.00--1.31-----3.19-3.190.008.600.00----0.00-52.94---60.31--------------0.00------68.88------
Olema Pharmaceuticals Inc0.00-122.68m503.08m87.00--2.57-----2.19-2.190.003.470.00----0.00-46.92-30.06-51.51-31.40------------0.00------7.76------
Taysha Gene Therapies Inc9.92m-22.77m506.21m52.00--6.67--51.05-0.0625-0.06250.04210.43330.0527----190,673.10-12.11---27.40-------229.67------0.328--517.55--32.80------
Alumis Inc0.00-238.77m514.66m145.00--1.47-----4.52-4.520.006.40----------------------------0.00-------38.47------
Data as of Nov 25 2024. Currency figures normalised to ProKidney Corp's reporting currency: US Dollar USD

Institutional shareholders

40.03%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley Investment Management, Inc.as of 30 Sep 202413.91m11.03%
Suvretta Capital Management LLCas of 30 Sep 202412.34m9.79%
BlackRock Fund Advisorsas of 30 Sep 20245.98m4.74%
GBM Administradora de Activos, SA de CV SOSIas of 30 Sep 20245.88m4.67%
The Vanguard Group, Inc.as of 30 Sep 20245.04m4.00%
Geode Capital Management LLCas of 30 Sep 20242.20m1.75%
Bleichroeder LPas of 30 Sep 20241.85m1.46%
SSgA Funds Management, Inc.as of 30 Sep 20241.43m1.13%
Brown University Investment Officeas of 30 Sep 20241.00m0.79%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024829.70k0.66%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.